APOE genotype and cognitive decline in a middle-aged cohort

Neurology

Volumn 64, Issue 2, 2005, Pages 268-276

  Blair, C K ^a   Folsom, A R ^a,f   Knopman, D S ^b   Bray, M S ^c   Mosley, T H ^d   Boerwinkle, E ^e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MAYO CLINIC   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; ATHEROSCLEROSIS; CAUCASIAN; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; DEMENTIA; DIABETES MELLITUS; FEMALE; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; POPULATION RESEARCH; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RISK ASSESSMENT;

EID: 12544259479     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000149643.91367.8A     Document Type: Article

References (33)

1. Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002;137:149-155.
2. Myers RH, Schaefer EJ, Wilson PW, et al. Apolipoprotein E epsilon4 association with dementia in a population-based study: the Framingham Study. Neurology 1996;46:673-677.
3. van Duijn CM, de Knijff P, Cruts M, et al. Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease. Nat Genet 1994;7:74-78.
4. Haan MN, Shemanski L, Jagust WJ, Manolio TA, Kuller L. The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 1999;282:40-46.
5. Bretsky P, Guralnik JM, Launer L, Albert M, Seeman TE. The role of APOE-epsilon4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging. Neurology 2003;60:1077-1081.
6. Mayeux R, Small SA, Tang M, Tycko B, Stern Y. Memory performance in healthy elderly without Alzheimer's disease: effects of time and apolipoprotein-E. Neurobiol Aging 2001;22:683-689.
7. Dik MG, Jonker C, Bouter LM, Geerlings MI, van Kamp GJ, Deeg DJ. APOE-epsilon4 is associated with memory decline in cognitively impaired elderly. Neurology 2000;54:1492-1497.
8. Collie A, Maruff P, Shafiq-Antonacci R, et al. Memory decline in healthy older people: implications for identifying mild cognitive impairment. Neurology 2001;56:1533-1538.
9. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349-1356.
10. Carmelli D, Swan GE, Reed T, et al. Midlife cardiovascular risk factors, ApoE, and cognitive decline in elderly male twins. Neurology 1998;50:1580-1585.
11. Knopman D, Boland LL, Mosley T, et al. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 2001;56:42-48.
12. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 2002;51:1256-1262.
13. Slooter AJ, van Duijn CM, Bots ML, et al. Apolipoprotein E genotype, atherosclerosis, and cognitive decline: the Rotterdam Study. J Neural Transm [Suppl] 1998;53:17-29.
14. Knopman DS, Ryberg S. A verbal memory test with high predictive accuracy for dementia of the Alzheimer type. Arch Neurol 1989;46:141-145.
15. Wechsler D. The Wechsler Adult Intelligence Scale-Revised. New York: Psychological Corp., 1981.
16. Lezak MD. Neuropsychological assessment. 3rd ed. New York: Oxford University Press, 1995.
17. Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol 1989;129:687-702.
18. National Heart Lung, and Blood Institute. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7), 2003. Available at http:// www.nhlbi.nih.gov/guidelines/ hypertension/jnc7full.pdf; accessed November 2004.
19. Yaffe K, Cauley J, Sands L, Browner W. Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women. Arch Neurol 1997;54:1110-1114.
20. Hyman BT, Gomez-Isla T, Briggs M, et al. Apolipoprotein E and cognitive change in an elderly population. Ann Neurol 1996;40:55-66.
21. Berr C, Dufouil C, Brousseau T, et al. Early effect of ApoE-epsilon 4 allele on cognitive results in a group of highly performing subjects: the EVA Study. Etude sur le Vieillissement Arteriel. Neurosci Lett 1996;218:9-12.
22. Peila R, White LR, Petrovich H, et al. Joint effect of the APOE gene and midlife systolic blood pressure on late-life cognitive impairment: the Honolulu-Asia Aging Study. Stroke 2001;32:2882-2889.
23. Fillenbaum GG, Landerman LR, Blazer DG, Saunders AM, Harris TB, Launer LJ. The relationship of APOE genotype to cognitive functioning in older African-American and Caucasian community residents. J Am Geriatr Soc 2001;49:1148-1155.
24. Evans DA, Bennett DA, Wilson RS, et al. Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol 2003;60:185-189.
25. Graff-Radford NR, Green RC, Go RC, et al. Association between apolipoprotein E genotype and Alzheimer disease in African American subjects. Arch Neurol 2002;59:594-600.
26. Sahota A, Yang M, Gao S, et al. Apolipoprotein E-associated risk for Alzheimer's disease in the African-American population is genotype dependent. Ann Neurol 1997;42:659-661.
27. Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 1995;333:1242-1247.
28. Nagy Z, Esiri MM, Jobst KA, et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 1995;69:757-761.
29. Eto M, Watanabe K, Ishii K. Reciprocal effects of apolipoprotein E alleles (epsilon 2 and epsilon 4) on plasma lipid levels in normolipidemic subjects. Clin Genet 1986;29:477-484.
30. Puglielli L, Tanzi RE, Kovacs DM. Alzheimer's disease: the cholesterol connection. Nat Neurosci 2003;6:345-351.
31. Launer LJ. Demonstrating the case that AD is a vascular disease: epidemiologic evidence. Ageing Res Rev 2002;1:61-77.
32. Sasaki N, Fukatsu R, Tsuzuki K, et al. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am J Pathol 1998;153:1149-1155.
33. Li YM, Dickson DW. Enhanced binding of advanced glycation endproducts (AGE) by the ApoE4 isoform links the mechanism of plaque deposition in Alzheimer's disease. Neurosci Lett 1997;226:155-158.